Heart failure guidelines: What's new?

被引：10

作者：

Papadimitriou, Lampros ^{[1
]}

Hamo, Carine E. ^{[1
]}

Butler, Javed ^{[1
]}

机构：

[1] SUNY Stony Brook, Dept Med, Div Cardiol, Stony Brook, NY 11794 USA

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2017年 / 27卷 / 05期

基金：

美国国家卫生研究院;

关键词：

Valsartan/sacubitril; Ivabradine; Guidelines; Heart failure; INHIBITOR IVABRADINE TRIAL; NEPRILYSIN INHIBITION; EJECTION FRACTION; RANDOMIZED-TRIAL; DOUBLE-BLIND; ENALAPRIL; OMAPATRILAT; SHIFT;

D O I：

10.1016/j.tcm.2017.01.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction.

引用

页码：316 / 323

页数：8

共 22 条

[1]

Administration UFaD, 2015, NEW DRUG APPL APPR L

[2] COMPARISON OF CANDOXATRIL AND ATRIAL-NATRIURETIC-FACTOR IN HEALTHY-MEN - EFFECTS ON HEMODYNAMICS, SYMPATHETIC ACTIVITY, HEART-RATE-VARIABILITY, AND ENDOTHELIN [J].

ANDO, S ;

RAHMAN, MA ;

BUTLER, GC ;

SENN, BL ;

FLORAS, JS .

HYPERTENSION, 1995, 26 (06) :1160-1166

[3] Update on ivabradine for heart failure [J].

Borer, Jeffrey S. ;

Tavazzi, Luigi .

TRENDS IN CARDIOVASCULAR MEDICINE, 2016, 26 (05) :444-449

[4]

Cleland JGF, LANCET, V1657-8, P351

[5] The funny current - Cellular basis for the control of heart rate [J].

DiFrancesco, Dario ;

Borer, Jeffrey S. .

DRUGS, 2007, 67 (Suppl 2) :15-24

[6] Funny channels in the control of cardiac rhythm and mode of action of selective blockers [J].

DiFrancesco, Dario .

PHARMACOLOGICAL RESEARCH, 2006, 53 (05) :399-406

[7] Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [J].

Fox, Kim ;

Ford, Ian ;

Steg, P. Gabriel ;

Tendera, Michal ;

Ferrari, Roberto .

LANCET, 2008, 372 (9641) :807-816

[8] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction [J].

Gaziano, Thomas A. ;

Fonarow, Gregg C. ;

Claggett, Brian ;

Chan, Wing W. ;

Deschaseaux-Voinet, Celine ;

Turner, Stuart J. ;

Rouleau, Jean L. ;

Zile, Michael R. ;

McMurray, John J. V. ;

Solomon, Scott D. .

JAMA CARDIOLOGY, 2016, 1 (06) :666-672

[9] New medications for heart failure [J].

Gordin, Jonathan S. ;

Fonarow, Gregg C. .

TRENDS IN CARDIOVASCULAR MEDICINE, 2016, 26 (06) :485-492

[10] Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial [J].

Kostis, OB ;

Packer, M ;

Black, HR ;

Schmieder, R ;

Henry, D ;

Levy, E .

AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (02) :103-111

← 1 2 3 →